Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
M.D. Anderson Cancer Center
With
Primary Objectives: * Atezolizumab +/- tiragolumab in combination with oxaliplatin and 5-fluorouracil (modified FOLFOX) therapy in the neoadjuvant setting will achieve a pathological complete response of approximately 20% in patients with localized esophageal and gastroesophageal (GEJ) adenocarcinoma. Secondary Objectives: * To evaluate safety and toxicity profile of intravenous Atezolizumab +/- Tiragolumab in combination with Oxaliplatin and 5-FU chemotherapy as neoadjuvant treatment for resectable esophageal or GEJ adenocarcinoma. * To assess the efficacy of the combination by tumor regression grade scoring in the surgical specimen. * To assess the overall safety and tolerability of adjuvant Atezolizumab +/- Tiragolumab in subjects with resected esophageal and GEJ cancer * To evaluate disease free survival (DFS) and overall survival (OS) in cohort 1 and cohort 2 * To explore changes in tumor stroma profile before and after immunotherapy in combination with chemotherapy
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
